Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Kazia Therapeutics: Edison Open House Healthcare 2022

Kazia Therapeutics: Edison Open House Healthcare 2022

Kazia Therapeutics — 9 videos in collection

More on this equity

Kazia Therapeutics’ lead asset is paxalisib, a PI3K inhibitor licensed from Genentech that can cross the BBB. It is entering a pivotal study for GBM and is being investigated for other brain cancers such as breast cancer brain metastases.
• Tell us about Kazia’s unique business model.
• What indications are you focusing on?
• What is the current status of paxalisib and what is the plan for the year ahead?
• How large do you anticipate the unmet need in the glioblastoma market to be?
• Is paxalisib being considered for any other brain cancers?
• What is the current status of EVT801 and what is the plan for the year ahead?
• Do the tumours you’re targeting have a genetic signature? What is the mechanism here?
• Which milestones should investors focus on in the coming year?

< Previous
Next >

You may also be interested in these:

Healthcare

Kazia Therapeutics webinar - Combating childhood brain cancer

Healthcare

EVT801, Kazia’s second programme, and capital markets

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free